---
title: "Israeli Pharmaceutical Research, Manufacturing and Exports"
description: "Israeli drug development can connect university research to company development, regulated manufacturing and export markets. Israel’s Central Bureau of Statistics recorded $3.7445 billion in 2022 exports for conventional and homeopathic pharmaceutical products."
url: "https://hasbara.co.il/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/academic-industrial-collaboration-in-israeli-drug-discovery"
type: "resource-page"
locale: "en"
categories: ["Israeli Pharmaceutical Industry: Teva and Generic Drugs"]
---

# Israeli Pharmaceutical Research, Manufacturing and Exports

*Israeli drug development can connect university research to company development, regulated manufacturing and export markets. Israel’s Central Bureau of Statistics recorded $3.7445 billion in 2022 exports for conventional and homeopathic pharmaceutical products.*

Israel’s pharmaceutical sector links academic laboratories, technology-transfer organizations, drug companies, manufacturing sites and export markets. Weizmann research licensed through Yeda led to Copaxone, while Technion researchers worked with Teva on the Parkinson’s medicine rasagiline. National trade data recorded $3.7445 billion in pharmaceutical-product exports in 2022.

## Research reaches industry through licensing

Universities generate discoveries, but companies usually carry out the later development needed to produce and market a medicine. A technology-transfer organization can license intellectual property to a company, which then funds development, clinical evaluation, manufacturing and regulatory submissions. Yeda, the Weizmann Institute’s commercial arm, describes its role in [transferring Institute research to industry](https://www.weizmann.ac.il/Biology/open_day_2008/book/Abstracts/yeda.pdf). Weizmann research on glatiramer acetate led to Copaxone, and Technion researchers John Finberg and Moussa Youdim developed rasagiline with Teva; the [Technion account of Azilect](https://www.technion.ac.il/en/blog/2022/03/from-tehran-to-haifa-from-selegiline-to-azilect/) describes that collaboration.

These are specific routes from research to products, not a complete measure of the sector. The path also includes manufacturing capacity and compliance with the rules of each market. Israel’s Ministry of Health inspects GMP at sites handling medicines and active ingredients, as explained by its [GMP inspectorate](https://www.gov.il/he/Departments/units/pharmaceutical-standards-and-quality-control).

## What the export figure measures

Israel’s Central Bureau of Statistics reported $3,744.5 million in 2022 exports for industry group 21, “Manufacture of conventional and homeopathic pharmaceutical products for human and veterinary uses.” This classification includes pharmaceutical products; it is not a combined figure for medicines and medical devices. The amount appears in [CBS Table 1 on exports by economic industry](https://www.cbs.gov.il/he/mediarelease/doclib/2023/281/16_23_281t1.pdf).

Exports show the scale of a manufacturing category, while research licenses and individual products show how discoveries can move toward the market. Teva is an important part of the industry’s history, described in [the company’s formation story](https://hasbara.co.il/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/the-early-history-and-consolidation-of-teva-pharmaceuticals), but the national export figure covers the wider pharmaceutical industry.

## Pages

- [From S.L.E. to Teva: The Industry's Early History](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/the-early-history-and-consolidation-of-teva-pharmaceuticals.md)
- [Eli Hurvitz and Teva's Global Expansion](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/eli-hurvitz-and-the-globalization-of-teva-pharmaceuticals.md)
- [Teva's API Business and the Global Drug Supply](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/teva-active-pharmaceutical-ingredients-and-the-global-drug-supply.md)
- [Copaxone: Weizmann Research to Multiple Sclerosis Treatment](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/the-breakthrough-development-and-global-success-of-copaxone.md)
- [Azilect: Technion Research and Clinical Development](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/the-clinical-development-of-azilect.md)
- [Drug Approval and Manufacturing in Israel](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/fda-approval-of-kfar-saba-and-israeli-drug-exports.md)

## Sources

- [weizmann.ac.il](https://www.weizmann.ac.il/Biology/open_day_2008/book/Abstracts/yeda.pdf)
- [technion.ac.il](https://www.technion.ac.il/en/blog/2022/03/from-tehran-to-haifa-from-selegiline-to-azilect/)
- [gov.il](https://www.gov.il/he/Departments/units/pharmaceutical-standards-and-quality-control)
- [cbs.gov.il](https://www.cbs.gov.il/he/mediarelease/doclib/2023/281/16_23_281t1.pdf)
